187 related articles for article (PubMed ID: 19067367)
1. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy.
Ellis RJ; Marquie-Beck J; Delaney P; Alexander T; Clifford DB; McArthur JC; Simpson DM; Ake C; Collier AC; Gelman BB; McCutchan JA; Morgello S; Grant I;
Ann Neurol; 2008 Nov; 64(5):566-72. PubMed ID: 19067367
[TBL] [Abstract][Full Text] [Related]
2. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.
Ellis RJ; Rosario D; Clifford DB; McArthur JC; Simpson D; Alexander T; Gelman BB; Vaida F; Collier A; Marra CM; Ances B; Atkinson JH; Dworkin RH; Morgello S; Grant I;
Arch Neurol; 2010 May; 67(5):552-8. PubMed ID: 20457954
[TBL] [Abstract][Full Text] [Related]
3. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
4. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.
Pettersen JA; Jones G; Worthington C; Krentz HB; Keppler OT; Hoke A; Gill MJ; Power C
Ann Neurol; 2006 May; 59(5):816-24. PubMed ID: 16634006
[TBL] [Abstract][Full Text] [Related]
5. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
6. Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings.
Vecchio AC; Marra CM; Schouten J; Jiang H; Kumwenda J; Supparatpinyo K; Hakim J; Sacktor N; Campbell TB; Tripathy S; Kumarasamy N; La Rosa A; Santos B; Silva MT; Kanyama C; Firnhaber C; Hosseinipour MC; Mngqibisa R; Hall C; Cinque P; Robertson K
Clin Infect Dis; 2020 Jun; 71(1):158-165. PubMed ID: 31630166
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
8. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.
Lichtenstein KA; Armon C; Baron A; Moorman AC; Wood KC; Holmberg SD;
Clin Infect Dis; 2005 Jan; 40(1):148-57. PubMed ID: 15614705
[TBL] [Abstract][Full Text] [Related]
9. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
10. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy.
Zhou L; Kitch DW; Evans SR; Hauer P; Raman S; Ebenezer GJ; Gerschenson M; Marra CM; Valcour V; Diaz-Arrastia R; Goodkin K; Millar L; Shriver S; Asmuth DM; Clifford DB; Simpson DM; McArthur JC;
Neurology; 2007 Jun; 68(24):2113-9. PubMed ID: 17562831
[TBL] [Abstract][Full Text] [Related]
11. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy.
Banerjee S; McCutchan JA; Ances BM; Deutsch R; Riggs PK; Way L; Ellis RJ
AIDS; 2011 Jan; 25(2):F1-6. PubMed ID: 21150557
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
13. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
Allavena C; Flandre P; Pugliese P; Valantin MA; Poizot-Martin I; Cabié A; Melliez H; Cuzin L; Duvivier C; Dellamonica P; Raffi F;
Scand J Infect Dis; 2012 Jan; 44(1):37-43. PubMed ID: 21851330
[TBL] [Abstract][Full Text] [Related]
14. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
15. Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings.
Marra CM; Boutin P; Collier AC
Neurology; 1998 Dec; 51(6):1678-81. PubMed ID: 9855522
[TBL] [Abstract][Full Text] [Related]
16. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women.
Hermes A; Squires K; Fredrick L; Martinez M; Pasley M; Trinh R; Norton M
HIV Clin Trials; 2012; 13(6):308-23. PubMed ID: 23195669
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
19. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Young J; Scherrer AU; Günthard HF; Opravil M; Yerly S; Böni J; Rickenbach M; Fux CA; Cavassini M; Bernasconi E; Vernazza P; Hirschel B; Battegay M; Bucher HC;
HIV Med; 2011 May; 12(5):299-307. PubMed ID: 20955357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
